rs151110146
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PVS1_StrongPM2PP5
The NM_005431.2(XRCC2):c.190C>T(p.Arg64*) variant causes a stop gained change. The variant allele was found at a frequency of 0.0000174 in 1,612,738 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_005431.2 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
XRCC2 | NM_005431.2 | c.190C>T | p.Arg64* | stop_gained | Exon 3 of 3 | ENST00000359321.2 | NP_005422.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
XRCC2 | ENST00000359321.2 | c.190C>T | p.Arg64* | stop_gained | Exon 3 of 3 | 1 | NM_005431.2 | ENSP00000352271.1 | ||
XRCC2 | ENST00000495707.1 | n.212C>T | non_coding_transcript_exon_variant | Exon 3 of 3 | 1 | |||||
XRCC2 | ENST00000698506.1 | c.22C>T | p.Arg8* | stop_gained | Exon 2 of 2 | ENSP00000513758.1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152138Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000241 AC: 6AN: 249124Hom.: 0 AF XY: 0.00000742 AC XY: 1AN XY: 134852
GnomAD4 exome AF: 0.0000164 AC: 24AN: 1460600Hom.: 0 Cov.: 32 AF XY: 0.0000165 AC XY: 12AN XY: 726568
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152138Hom.: 0 Cov.: 32 AF XY: 0.0000404 AC XY: 3AN XY: 74308
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:3
This variant is a single amino acid change from Arginine to a premature translational stop signal at codon 64 of the XRCC2 protein. This is expected to result in an absent or disrupted protein product. This variant has been described in the international literature in individuals undergoing panel testing for hereditary syndrome (PMID: 31159747). -
- -
The p.R64* variant (also known as c.190C>T), located in coding exon 3 of the XRCC2 gene, results from a C to T substitution at nucleotide position 190. This changes the amino acid from an arginine to a stop codon within coding exon 3. This alteration was seen in one patient from a Chinese breast cancer cohort (Sun J et al. Clin. Cancer Res. 2017 Oct;23(20):6113-6119). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation. As such, this alteration is interpreted as a disease-causing mutation. -
Fanconi anemia complementation group U;C5436888:Spermatogenic failure 50;C5436889:Premature ovarian failure 17 Pathogenic:1
- -
not provided Uncertain:1
This sequence change creates a premature translational stop signal (p.Arg64*) in the XRCC2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 217 amino acid(s) of the XRCC2 protein. This variant is present in population databases (rs151110146, gnomAD 0.009%). This premature translational stop signal has been observed in individual(s) with a personal or family history of breast and/or ovarian cancer and/or pancreatic ductal adenocarcinoma (PMID: 28724667, 31159747, 35171259). ClinVar contains an entry for this variant (Variation ID: 486729). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at